Roth Capital Remains a Buy on Moleculin Biotech (MBRX)

In a report issued on March 20, Jonathan Aschoff from Roth Capital maintained a Buy rating on Moleculin Biotech (MBRXResearch Report), with a price target of $5.00. The company’s shares closed last Thursday at $1.07.

According to TipRanks.com, Aschoff is currently ranked with 0 stars on a 0-5 stars ranking scale, with an average return of -2.2% and a 40.8% success rate. Aschoff covers the Healthcare sector, focusing on stocks such as Entasis Therapeutics Holdings, Inovio Pharmaceuticals, and Aridis Pharmaceuticals.

Moleculin Biotech has an analyst consensus of Strong Buy, with a price target consensus of $3.33, which is a 242.9% upside from current levels. In a report issued on June 9, Maxim Group also initiated coverage with a Buy rating on the stock with a $3.00 price target.

See today’s analyst top recommended stocks >>

Based on Moleculin Biotech’s latest earnings release for the quarter ending September 30, the company reported a quarterly GAAP net loss of $3.4 million. In comparison, last year the company had a GAAP net loss of $4.15 million.

TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.

Moleculin Biotech, Inc. is a clinical stage pharmaceutical company, which focuses on the development of oncology drug candidates. Its Annamycin product candidate helps in the treatment of relapsed or refractory acute myeloid leukemia. The company’s preclinical small molecule portfolios focus on the modulation of hard-to-target tumor cell signaling mechanisms and the metabolism of tumors. Moleculin Biotech was founded by Walter V. Klemp, Donald H. Picker and Waldemar Priebe on July 28, 2015 and is headquartered in Houston, TX.